PE20220169A1 - Compuestos macrociclicos como agonistas de sting - Google Patents
Compuestos macrociclicos como agonistas de stingInfo
- Publication number
- PE20220169A1 PE20220169A1 PE2021001577A PE2021001577A PE20220169A1 PE 20220169 A1 PE20220169 A1 PE 20220169A1 PE 2021001577 A PE2021001577 A PE 2021001577A PE 2021001577 A PE2021001577 A PE 2021001577A PE 20220169 A1 PE20220169 A1 PE 20220169A1
- Authority
- PE
- Peru
- Prior art keywords
- ring
- optionally substituted
- sting
- macrocyclic compounds
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Abstract
Se refiere a compuestos macrociclicos de formula general (I) en donde, G1 se selecciona entre el anillo A o >CH-(CH)n-anillo A; G2 es -CH=CH-; el anillo A se selecciona entre heterociclilo y heteroarilo, cada uno opcionalmente sustituidos; el anillo B es un carbociclico aromatico; el anillo C es heteroarilo de cinco miembros opcionalmente sustituido; R1 es -CON(R3 )2; R2 se selecciona entre hidrogeno, alquilo C1-C6 opcionalmente sustituido y cicloalquilo C3-C5 monociclico opcionalmente sustituido; m es entre 0 o 1; n es entre 0 a 2; o es 1; p es entre 0 a 2. Un compuesto seleccionado es (E)-8-(8-oxa-3-azabiciclo[3.2.1]octan-3- il)-1,15-bis(1-etil-3-metil-1H-pirazol-5- carboxamido)-8,9,16,19-tetrahidro-7H-6,10-dioxa-2,14,15a,19a-tetraazaciclopentadeca[3,2,1-cd: 8,9,10 -c'd'] diinden-4,12-dicarboxamida. Dichos compuestos son agonistas de STING (estimulador de genes de interferon). Tambien refiere a una composicion farmaceutica que los comprende, siendo utiles para el tratamiento de una enfermedad o afeccion donde la que la activacion de STING es beneficiosa, tal como el cancer o enfermedades infecciosas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921012258 | 2019-03-28 | ||
| IN201921046194 | 2019-11-13 | ||
| PCT/IB2020/052654 WO2020194160A1 (en) | 2019-03-28 | 2020-03-21 | Macrocyclic compounds as sting agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220169A1 true PE20220169A1 (es) | 2022-01-28 |
Family
ID=70293003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001577A PE20220169A1 (es) | 2019-03-28 | 2020-03-21 | Compuestos macrociclicos como agonistas de sting |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220144852A1 (es) |
| EP (1) | EP3946610A1 (es) |
| JP (1) | JP2022527306A (es) |
| KR (1) | KR20210146370A (es) |
| CN (1) | CN113631228B (es) |
| AU (1) | AU2020245263A1 (es) |
| BR (1) | BR112021018947A2 (es) |
| CA (1) | CA3132508A1 (es) |
| CL (1) | CL2021002480A1 (es) |
| CO (1) | CO2021012559A2 (es) |
| CR (1) | CR20210495A (es) |
| EC (1) | ECSP21071644A (es) |
| IL (1) | IL286526A (es) |
| MA (1) | MA55517A (es) |
| MX (1) | MX2021011686A (es) |
| PE (1) | PE20220169A1 (es) |
| SG (1) | SG11202109191SA (es) |
| WO (1) | WO2020194160A1 (es) |
| ZA (1) | ZA202106629B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20220937A1 (es) * | 2019-07-22 | 2022-05-31 | Lupin Ltd | Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos |
| US11155567B2 (en) | 2019-08-02 | 2021-10-26 | Mersana Therapeutics, Inc. | Sting agonist compounds and methods of use |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| BR112023014128A2 (pt) * | 2021-01-15 | 2023-10-31 | Seagen Inc | Conjugados de anticorpo-fármaco imunomodulatórios |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| SG11201704628VA (en) * | 2015-02-05 | 2017-07-28 | Merck Patent Gmbh | Macrocyclic compounds as irak1/4 inhibitors and uses thereof |
| CA3030582A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| US10981901B1 (en) | 2016-04-07 | 2021-04-20 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| EP3440072B1 (en) | 2016-04-07 | 2020-01-29 | GlaxoSmithKline Intellectual Property Development Ltd | Heterocyclic amides useful as protein modulators |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| WO2018234805A1 (en) * | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | SMALL MOLECULAR MODULATORS OF HUMAN STING |
| SG11201912397RA (en) | 2017-06-22 | 2020-01-30 | Curadev Pharma Ltd | Small molecule modulators of human sting |
| EP3658138B1 (en) | 2017-07-27 | 2023-04-19 | Stingray Therapeutics, Inc. | Substituted-3h-imidazo(4,5-c)pyridine and 1h-pyrrolo(2,3-c)pyridine series of novel ectonucleotide pyrophsphatase/phosphodiestrase-1 (enpp1) and stimulator for interferon genes (sting) modulator as cancer immunotherapeutics |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
-
2020
- 2020-03-21 SG SG11202109191SA patent/SG11202109191SA/en unknown
- 2020-03-21 AU AU2020245263A patent/AU2020245263A1/en active Pending
- 2020-03-21 US US17/598,524 patent/US20220144852A1/en active Pending
- 2020-03-21 KR KR1020217035108A patent/KR20210146370A/ko unknown
- 2020-03-21 BR BR112021018947A patent/BR112021018947A2/pt unknown
- 2020-03-21 CR CR20210495A patent/CR20210495A/es unknown
- 2020-03-21 MX MX2021011686A patent/MX2021011686A/es unknown
- 2020-03-21 PE PE2021001577A patent/PE20220169A1/es unknown
- 2020-03-21 CN CN202080025785.1A patent/CN113631228B/zh active Active
- 2020-03-21 CA CA3132508A patent/CA3132508A1/en active Pending
- 2020-03-21 EP EP20719719.5A patent/EP3946610A1/en active Pending
- 2020-03-21 WO PCT/IB2020/052654 patent/WO2020194160A1/en active Application Filing
- 2020-03-21 JP JP2021557830A patent/JP2022527306A/ja active Pending
- 2020-03-21 MA MA055517A patent/MA55517A/fr unknown
-
2021
- 2021-09-08 ZA ZA2021/06629A patent/ZA202106629B/en unknown
- 2021-09-19 IL IL286526A patent/IL286526A/en unknown
- 2021-09-24 EC ECSENADI202171644A patent/ECSP21071644A/es unknown
- 2021-09-24 CL CL2021002480A patent/CL2021002480A1/es unknown
- 2021-09-24 CO CONC2021/0012559A patent/CO2021012559A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021012559A2 (es) | 2021-09-30 |
| KR20210146370A (ko) | 2021-12-03 |
| BR112021018947A2 (pt) | 2022-02-08 |
| JP2022527306A (ja) | 2022-06-01 |
| ZA202106629B (en) | 2022-07-27 |
| EP3946610A1 (en) | 2022-02-09 |
| IL286526A (en) | 2021-10-31 |
| CL2021002480A1 (es) | 2022-04-29 |
| CR20210495A (es) | 2021-10-18 |
| CA3132508A1 (en) | 2020-10-01 |
| CN113631228A (zh) | 2021-11-09 |
| ECSP21071644A (es) | 2021-12-30 |
| SG11202109191SA (en) | 2021-09-29 |
| AU2020245263A1 (en) | 2021-10-07 |
| MX2021011686A (es) | 2021-10-22 |
| US20220144852A1 (en) | 2022-05-12 |
| MA55517A (fr) | 2022-02-09 |
| WO2020194160A1 (en) | 2020-10-01 |
| CN113631228B (zh) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220169A1 (es) | Compuestos macrociclicos como agonistas de sting | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PE20020872A1 (es) | DERIVADOS DE FENETANOLAMINA COMO AGONISTAS DE LOS ß2-ADRENORECEPTORES | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
| PE20190705A1 (es) | COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING | |
| PA8547601A1 (es) | Inhibidores de la proteasa del vih, composiciones que los contienen, sus usos farmaceuticos y materiales para su sintesis | |
| PE20161251A1 (es) | Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4 | |
| AR011093A1 (es) | Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso. | |
| ECSP066858A (es) | Inhibidores de gsk-3 | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| AR020851A2 (es) | Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| AR073701A1 (es) | Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas. | |
| PE20140411A1 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
| PE20091349A1 (es) | Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| AR058055A1 (es) | Analogos de feniletilamina y su uso para el tratamiento del glaucoma | |
| AR058800A1 (es) | Heterociclos condensados con anillos bencenicos como inhibidores de comt, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento del mal de parkinson |